These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 15996054)
1. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. Jacobsson LT; Turesson C; Gülfe A; Kapetanovic MC; Petersson IF; Saxne T; Geborek P J Rheumatol; 2005 Jul; 32(7):1213-8. PubMed ID: 15996054 [TBL] [Abstract][Full Text] [Related]
2. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Jacobsson LT; Turesson C; Nilsson JA; Petersson IF; Lindqvist E; Saxne T; Geborek P Ann Rheum Dis; 2007 May; 66(5):670-5. PubMed ID: 17158824 [TBL] [Abstract][Full Text] [Related]
3. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133 [TBL] [Abstract][Full Text] [Related]
4. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534 [TBL] [Abstract][Full Text] [Related]
5. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Romanus V; Klareskog L; Feltelius N Arthritis Rheum; 2005 Jul; 52(7):1986-92. PubMed ID: 15986370 [TBL] [Abstract][Full Text] [Related]
6. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Wolfe F; Michaud K Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349 [TBL] [Abstract][Full Text] [Related]
7. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Wolfe F; Michaud K Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100 [TBL] [Abstract][Full Text] [Related]
8. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516 [TBL] [Abstract][Full Text] [Related]
9. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Peters MJ; van Halm VP; Voskuyl AE; Smulders YM; Boers M; Lems WF; Visser M; Stehouwer CD; Dekker JM; Nijpels G; Heine R; Dijkmans BA; Nurmohamed MT Arthritis Rheum; 2009 Nov; 61(11):1571-9. PubMed ID: 19877093 [TBL] [Abstract][Full Text] [Related]
10. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD; Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464 [TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Solomon DH; Avorn J; Katz JN; Weinblatt ME; Setoguchi S; Levin R; Schneeweiss S Arthritis Rheum; 2006 Dec; 54(12):3790-8. PubMed ID: 17136752 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular death in rheumatoid arthritis: a population-based study. Maradit-Kremers H; Nicola PJ; Crowson CS; Ballman KV; Gabriel SE Arthritis Rheum; 2005 Mar; 52(3):722-32. PubMed ID: 15751097 [TBL] [Abstract][Full Text] [Related]
14. Patterns of cardiovascular risk in rheumatoid arthritis. Solomon DH; Goodson NJ; Katz JN; Weinblatt ME; Avorn J; Setoguchi S; Canning C; Schneeweiss S Ann Rheum Dis; 2006 Dec; 65(12):1608-12. PubMed ID: 16793844 [TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. Fabris M; Tolusso B; Di Poi E; Assaloni R; Sinigaglia L; Ferraccioli G J Rheumatol; 2002 Sep; 29(9):1847-50. PubMed ID: 12233877 [TBL] [Abstract][Full Text] [Related]
16. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661 [TBL] [Abstract][Full Text] [Related]
17. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. Wållberg-Jonsson S; Johansson H; Ohman ML; Rantapää-Dahlqvist S J Rheumatol; 1999 Dec; 26(12):2562-71. PubMed ID: 10606363 [TBL] [Abstract][Full Text] [Related]
18. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Raaschou P; Simard JF; Neovius M; Askling J; Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular morbidity and mortality remain similar in two cohorts of patients with long-standing rheumatoid arthritis seen in 1978 and 1995 in Malmö, Sweden. Bergström U; Jacobsson LT; Turesson C Rheumatology (Oxford); 2009 Dec; 48(12):1600-5. PubMed ID: 19858122 [TBL] [Abstract][Full Text] [Related]
20. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]